Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6602 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2024-11-15 (pharmnewskz.com)
Innovative Solutions in Medicine: Game-Changing Research
Kazakhstan Pharmaceutical Bulletin is an information and analytical newspaper for pharmacists. All about the pharmaceutical market. Pharmacy news, pharmaceuticals, pharmacy, healthcare, legislation. Electronic version of KFV
Read more
2024-09-13 (pharmnewskz.com)
Biogen Tried New Spinraza Treatment for SMA with Higher Doses
Kazakhstan Pharmaceutical Bulletin is an information and analytical newspaper for pharmacists. All about the pharmaceutical market. Pharmacy news, pharmaceuticals, pharmacy, healthcare, legislation. Electronic version of KFV
Read more
2024-08-05 (ura.news)
The US company Biogen filed a lawsuit against the Russian Ministry of Health
The US company Biogen filed a lawsuit against the Russian Ministry of Health
Read more
2024-06-25 (canadianinsider.com)
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
The only place for free North American stock rankings incorporating insider commitment. Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. Home of the Canadian Insider Club which offers alerts and premium research.
Read more
2024-05-27 (halconesypalomas.com)
The New York law boutique that seeks a class action lawsuit against Ecopetrol, won a lawsuit against Apple, and is going after Morgan Stanley, Biogen and Hsbc
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of buyers of Hsbc Holdings plc. The investigation concerns whether Hsbc has violated federal securities laws because when announcing its financial and operating results for 2023 it revealed a charge for
Read more
2024-05-23 (businesswire.com)
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Colorado on be
Read more
2024-01-08 (lakemedelsvarlden.se)
The NT Council's new chairman: "Difficult questions are fun" - LäkemedelsVärlden
"I think difficult questions are fun." says the NT Council's new chairman, doctor Åsa Derolf. She cannot refuse such an exciting assignment.
Read more
2023-12-29 (marketbeat.com)
Biogen Inc. (NASDAQ:BIIB) Stock Position Raised by Czech National Bank
Czech National Bank raised its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 47.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,312 shares of the biotechnology company's stock
Read more
2023-11-14 (finmarket.ru)
Investbank
Investment bank ``Sinara'' maintains ``hold'' rating for Tesla shares with outlook
Read more
2023-10-23 (reut.rs)
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of Roche's blockbuster rheumatoid arthritis drug Actemra, according to a filing on Monday in Massachusetts federal court.
Read more
2023-10-11 (bloomberglaw.com)
Biogen Investors Can Proceed With Alzheimer’s Drug Trial Lawsuit
Biogen Inc. investors will have another chance to prove some of their claims that the pharmaceutical company violated federal securities laws in the way it presented data about the efficacy of its expensive Alzheimer’s drug, Aduhelm.
Read more
2023-07-28 (businesswire.com)
RETA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Reata Pharmaceuticals, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) to Biogen Inc. for $172
Read more